FMP
Xenon Pharmaceuticals Inc.
XENE
NASDAQ
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
35.32 USD
0.14 (0.396%)
XENE Financial Statements
Year
2024
2023
2022
2021
Total Revenue
0
0
9.43M
18.44M
Cost of Revenue
0
167.51M
105.77M
75.46M
Gross Profit
0
-167.51M
-96.33M
-57.03M
Operating Expenses
279.3M
46.54M
138.58M
97.43M
Research and Development
210.39M
167.51M
105.77M
75.46M
Selling, General & Administrative Expenses
68.9M
46.54M
32.81M
21.97M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
68.9M
46.54M
32.81M
21.97M
Other Expenses
0
-167.51M
3.89M
105k
Operating Income
-279.3M
-214.05M
-129.14M
-78.99M
Total Other Income/Expenses Net
40.88M
31.37M
3.89M
105k
Income Before Tax
-238.42M
-182.69M
-125.25M
-78.89M
Income Tax
4.09M
-292k
118k
-6k
Net Income
-234.33M
-182.39M
-125.37M
-78.88M
Basic EPS
-3.01
-2.73
-2.07
-1.81
EPS Diluted
-3.01
-2.73
-2.07
-1.81
Basic Average Shares
77.89M
66.89M
60.54M
43.63M
Diluted Average Shares
77.89M
66.89M
60.54M
43.63M
EBITDA
-279.3M
-210.51M
-127.52M
-78.09M
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-665.14M
-482.75M
-357.37M
-278.49M
Net Income
-234.33M
-182.39M
-125.37M
-78.88M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-899.47M
-665.14M
-482.75M
-357.37M
Other Distributions
-234.33M
-182.39M
-125.37M
-78.88M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
18.22M
18.85M
16.91M
12.52M
Annual Depreciation
0
3.54M
1.62M
906k
Capital Expenditure
0
-5.62M
-2.89M
-2.05M
Net PPE
18.22M
20.92M
18.18M
13.67M
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
